Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acellular pertussis vaccine-Novartis Vaccines-pertussis-tetanus-diphtheria
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This investigational vaccine is an acellular pertussis (aP) booster, often formulated as a TdaP vaccine (including tetanus and diphtheria toxoids), developed by Novartis Vaccines (now part of GSK). Its distinguishing feature is the use of a genetically detoxified pertussis toxin (PTgen), specifically the 9K/129G mutant, rather than the chemically inactivated toxin found in traditional vaccines. This genetic modification preserves the native protein structure, potentially enhancing immunogenicity. The vaccine also includes other pertussis antigens such as filamentous hemagglutinin (FHA) and pertactin (PRN). It is designed to prevent pertussis, tetanus, and diphtheria in adults and was evaluated in Phase I clinical trials to compare its safety and immunogenicity against licensed comparators.
- Other names
- investigational TdaP vaccineNovartis TdaP booster vaccineacellular pertussis and tetanus-diphtheria-acellular pertussis booster vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on acellular pertussis vaccine-Novartis Vaccines-pertussis-tetanus-diphtheria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acellular pertussis vaccine-Novartis Vaccines-pertussis-tetanus-diphtheria.